New pill targets Hard-to-Treat cancers with specific genetic flaw
NCT ID NCT07394374
Summary
This early-stage trial is testing a new oral drug called CG001419 for adults with advanced solid tumors that have specific changes in the NTRK gene and have stopped responding to standard treatments. The study first aims to find a safe and effective dose, then see if the drug can shrink tumors. Participants will take the drug as a tablet until their cancer progresses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS HARBORING NTRK FUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanxi Provincial Cancer Hospital
RECRUITINGTaiyuan, China
Contact
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
Contact
-
The Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sir Run Run Shaw Hospital, Affiliated to Zhejiang University School of Medicine
RECRUITINGHangzhou, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, China
Contact
-
Zhejiang Provincial Cancer Hospital
RECRUITINGHangzhou, China
Contact
Conditions
Explore the condition pages connected to this study.